Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
Company | Change | P/E (TTM) |
---|---|---|
XONIntrexon Corp. | +2.51% | - |
XLRNAcceleron Pharma Inc. | -0.03% | - |
XNCRXencor Inc. | +2.05% | - |
BLCMBellicum Pharmaceuticals Inc. | +0.83% | - |
Seres Therapeutics, Inc. is a microbiome therapeutics platform company, which engages in developing biological drugs. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome....
Q2 2016 Estimate Trends | |
---|---|
Current: | $-0.41 |
1 month ago: | $-0.43 |
3 months ago: | $-0.11 |
Q3 2016 Estimate Trends | |
---|---|
Current: | $-0.47 |
1 month ago: | $-0.32 |
3 months ago: | $-0.33 |
Mar 2016 | 5-quarter trend | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income Growth | -147.20% | | ||||||||||
Sales or Revenue | 2.71 M | | ||||||||||
Sales or Revenue Growth | - | |||||||||||
EBITDA | -19.53 M | | ||||||||||
2015 | 5-year trend | |||||||||||
Net Income Growth | -227.85% | | ||||||||||
Sales or Revenue | - | |||||||||||
Sales or Revenue Growth | - | |||||||||||
EBITDA | -54.13 M | |